Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00671749 · ClinicalTrials.gov registry record · Phase 4
Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris
A Phase 4 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT00671749 is a Phase 4 study that has completed, run by Galderma R&D. The registered enrollment target is 100 participants.
The verdict
NCT00671749, a Phase 4 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
This study is to determine the efficacy and safety of 12 week treatment with Differin® Gel 0.3% applied in the evening, in combination with Duac® (Clindamycin/Benzoyl Peroxide Gel) applied in the morning, in Subjects with Acne vulgaris.
Interventions
- DRUG adapalene gel, 0.3%
- DRUG clindamycin/benzoyl peroxide gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2007-12 |
| Est. Completion | 2008-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00671749
The ClinicalTrials.gov registry entry for NCT00671749 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which adapalene gel, 0.3% is the first listed.
NCT00671749 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00671749 about?
NCT00671749 is a clinical study titled "Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris". This study is to determine the efficacy and safety of 12 week treatment with Differin® Gel 0.3% applied in the evening, in combination with Duac® (Clindamycin/Benzoyl Peroxide Gel) applied in the morning, in Subjects with Acne vulgaris.
What is the current status of trial NCT00671749?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2007-12. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00671749?
The interventions under investigation include: adapalene gel, 0.3% (DRUG), clindamycin/benzoyl peroxide gel (DRUG).
Who is sponsoring clinical trial NCT00671749?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.